Keap1-Nrf2-IN-13
Modify Date: 2025-08-25 18:55:50
Keap1-Nrf2-IN-13 structure
|
Common Name | Keap1-Nrf2-IN-13 | ||
|---|---|---|---|---|
| CAS Number | 2456294-92-9 | Molecular Weight | 620.69 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H32N2O10S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Keap1-Nrf2-IN-13Keap1-Nrf2-IN-13 is a Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with an IC50 value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forming hydrogen bond with the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers[1]. |
| Name | Keap1-Nrf2-IN-13 |
|---|
| Description | Keap1-Nrf2-IN-13 is a Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with an IC50 value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forming hydrogen bond with the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.15 μM (Keap1-Nrf2 PPI)[1] |
| In Vitro | Keap1-Nrf2-IN-13 (compound 21a, 0.5-50 μM) has inhibitory effect against Keap1-Nrf2 protein–protein interaction (PPI) with an IC50 value of 0.15 μM (fluorescence polarization (FP) assay)[1]. Keap1-Nrf2-IN-13 (0.1 mM, 90 min) has metabolic stability in the presence of human liver microsomes[1]. Keap1-Nrf2-IN-13 forms hydrogen bond interactions with the key polar residues (Asn414, Arg415, Arg483, Gln530), resulting in strong binding affinities to the Keap1 protein (docking assay)[1]. |
| References |
| Molecular Formula | C28H32N2O10S2 |
|---|---|
| Molecular Weight | 620.69 |